Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Merck
Harvard Business School
McKesson
Baxter
AstraZeneca
McKinsey

Last Updated: October 20, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR AMBRISENTAN

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Ambrisentan

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00091598 ARIES - Ambrisentan in Patients With Moderate to Severe Pulmonary Arterial Hypertension (PAH) Completed Gilead Sciences Phase 3 2004-01-01 The primary objective is to determine the effect of ambrisentan on exercise capacity in subjects with PAH.
NCT00380068 Safety and Efficacy Study of Ambrisentan in Subjects With Pulmonary Hypertension Completed Gilead Sciences Phase 3 2006-08-01 The primary objective of this study was to evaluate the safety and efficacy of ambrisentan in a broad population of participants with pulmonary hypertension (PH). Secondary objectives of this study were to evaluate the effects of ambrisentan on other clinical measures of pulmonary arterial hypertension (PAH), long-term treatment success, and survival.
NCT00423202 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess Safety and Efficacy of Ambrisentan in Subjects With Pulmonary Arterial Hypertension. Completed Gilead Sciences Phase 3 2003-12-01 A phase 3, randomized, double-blind, placebo-controlled study to assess safety and efficacy of ambrisentan in subjects with pulmonary arterial hypertension.
NCT00423592 Phase 2 Study of Ambrisentan for Liver Function Test Rescue in Pulmonary Arterial Hypertension Completed Gilead Sciences Phase 2 2005-05-01 This Phase 2 study was to determine the incidence of increased serum aminotransferase concentrations (alanine aminotransferase [ALT] and/or aspartate aminotransferase [AST]), as well as the overall safety and tolerability of ambrisentan, in participants with pulmonary arterial hypertension (PAH), idiopathic PAH (IPAH), or familial PAH (FPAH) who had previously discontinued ERA therapy (bosentan or sitaxsentan) due to increased serum ALT or AST concentrations.
NCT00423748 Study to Assess Safety and Efficacy of Ambrisentan in Subjects With Pulmonary Arterial Hypertension. Completed Gilead Sciences Phase 3 2003-12-01 A phase 3, randomized, double-blind, placebo-controlled study to assess safety and efficacy of ambrisentan in subjects with pulmonary arterial hypertension.
NCT00424021 Phase 2 Extension Study of Ambrisentan in Pulmonary Arterial Hypertension Completed Gilead Sciences Phase 2 2003-04-01 AMB-220-E is an international, multicenter, open-label study examining the long-term safety of ambrisentan (BSF 208075) in subjects who have previously completed Myogen study NCT00046319, "A Phase II, Randomized, Double-Blind, Dose-Controlled, Dose-Ranging, Multicenter Study of BSF 208075 Evaluating Exercise Capacity in Subjects with Moderate to Severe Pulmonary Arterial Hypertension".
NCT00540436 Evaluate the Efficacy, Safety and Pharmacokinetics of GSK1325760A in the Treatment of Pulmonary Arterial Hypertension Completed GlaxoSmithKline Phase 2 2007-08-01 The primary objective of this study is to evaluate the effect of GSK1325760A on improvement in exercise capacity in subjects with pulmonary arterial hypertension (PAH). The secondary objectives of this study are to evaluate administration of GSK1325760A on: - The safety and tolerability - Improvement of PAH - The steady-state plasma pharmacokinetics of GSK1325760A
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Ambrisentan

Condition Name

Condition Name for Ambrisentan
Intervention Trials
Pulmonary Hypertension 15
Pulmonary Arterial Hypertension 14
Hypertension, Pulmonary 7
Systemic Sclerosis 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Ambrisentan
Intervention Trials
Hypertension 40
Hypertension, Pulmonary 27
Familial Primary Pulmonary Hypertension 24
Scleroderma, Systemic 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Ambrisentan

Trials by Country

Trials by Country for Ambrisentan
Location Trials
United States 226
Germany 41
Canada 32
Australia 22
Italy 21
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Ambrisentan
Location Trials
Massachusetts 14
California 13
North Carolina 11
Texas 11
Pennsylvania 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Ambrisentan

Clinical Trial Phase

Clinical Trial Phase for Ambrisentan
Clinical Trial Phase Trials
Phase 4 10
Phase 3 14
Phase 2/Phase 3 2
[disabled in preview] 27
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Ambrisentan
Clinical Trial Phase Trials
Completed 25
Recruiting 9
Unknown status 5
[disabled in preview] 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Ambrisentan

Sponsor Name

Sponsor Name for Ambrisentan
Sponsor Trials
Gilead Sciences 22
GlaxoSmithKline 11
University of Calgary 2
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Ambrisentan
Sponsor Trials
Other 71
Industry 41
NIH 4
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Colorcon
Baxter
Johnson and Johnson
Medtronic
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.